With many biotechs and pharmas needing to fill impending revenue holes coming later in the decade, M&A is posed to pick up, but not until government and regulatory uncertainty settles down. Dealmaking ...

The IXP Lifesciences Catalyst Fund has a greenshoe option of Rs 100 crore with an investment horizon of 3-5 years targeting ...

(Corrects third to last paragraph to say "the erosion from LOEs (loss of exclusivity)", not "from LOEs (levels of evidence)") ...

For example, Brittany found that drugs being developed by Generate were modified versions of existing antibodies, and that ...

Biotech firm Phytome Life Sciences plans to establish a headquarters in Saudi Arabia in a bid to accelerate commercialization ...

The fund aims to build a portfolio of 20-25 companies that address gaps in services and products across pharmaceuticals, ...

Good news for the sector came January 23 when global pharmaceutical giant AstraZeneca plc announced an eye-popping $820 ...

Of the 102 company launches or series A financings since October 2023, just nine had a woman at the helm, according to a ...

Variant Bio recently announced a multimillion-dollar deal with a pharmaceutical company, and some of that money will go to ...

Leading American genomic sequencing firm Illumina says it is evaluating Beijing’s announcement with hope of ‘positive ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.